78
Participants
Start Date
July 26, 2018
Primary Completion Date
July 29, 2019
Study Completion Date
July 29, 2019
AZD8154
SAD Part 1; 6 cohorts which receive single dosing. One cohort is invited back for large particle administration. Part 2; 1 cohort which receives IV dose and then inhaled administration of AZD8154. MAD Part 3; 3 cohorts will receive inhaled multiple dosing. Additional doses are provisional and could be adjusted based on the emerging data from the previous dose by the safety review committee (SRC).
Research Site, Berlin
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY